Stockscreener 앱 받기
1.89
12.20%
0.21
전일 마감가:
$1.68
열려 있는:
$1.7
하루 거래량:
1.23M
Relative Volume:
4.23
시가총액:
$103.01M
수익:
-
순이익/손실:
$-151.16M
주가수익비율:
-0.6364
EPS:
-2.97
순현금흐름:
$-130.08M
1주 성능:
+25.67%
1개월 성능:
+63.91%
6개월 성능:
+263.83%
1년 성능:
+42.80%
1일 변동 폭
$1.66
$2.00
1주일 범위
$1.36
$2.00
52주 변동 폭
$0.404
$2.27
AIx 온콜로지 Stock (ALXO) Company Profile
명칭
Alx Oncology Holdings Inc
전화
650-466-7125
주소
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.90 | 91.09M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.68 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.23 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
846.98 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
350.49 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
345.40 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
AIx 온콜로지 Stock (ALXO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-06 | 개시 | UBS | Buy |
| 2021-02-10 | 개시 | H.C. Wainwright | Buy |
| 2020-08-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 개시 | Credit Suisse | Outperform |
| 2020-08-11 | 개시 | Jefferies | Buy |
| 2020-08-11 | 개시 | Piper Sandler | Overweight |
모두보기
AIx 온콜로지 주식(ALXO)의 최신 뉴스
Wilson Sonsini Advises ALX Oncology on Public Offering - Wilson Sonsini
CD47 Protein May Predict Evorpacept Success in Metastatic Breast Cancer - Cure Today
ALX Oncology Prices $150 Mln Offering Of Shares And Pre-funded Warrants - Nasdaq
ALX Oncology announces pricing of underwritten offering; shares up nearly 15% - MSN
ALX Oncology prices $150 million stock offering at $1.57 per share - Investing.com Nigeria
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera in Advanced HER2-Positive Breast Cancer - Investing News Network
ALX Oncology reports CD47 biomarker findings in breast cancer trial By Investing.com - Investing.com Nigeria
ALXO Unveils Promising Data from Evorpacept Trial in Breast Canc - GuruFocus
ALX Oncology announces major underwritten public equity offering - TipRanks
ALX Oncology Announces Pricing of Underwritten Offering - The Manila Times
Biotech ALX Oncology raises $150M to fund cancer drug trials - Stock Titan
ALX Oncology reports CD47 biomarker findings in breast cancer trial - Investing.com
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - The Manila Times
ALX Oncology Holdings Inc Announces New Clinical Trial Data - TradingView
What is ALX Oncology Holdings Inc.’s book value per shareTrade Exit Report & Daily Chart Pattern Signals - Mfd.ru
Can ALX Oncology Holdings Inc. reach all time highs this yearDip Buying & Daily Volume Surge Trade Alerts - Mfd.ru
IPO Launch: Is ALX Oncology Holdings Inc affected by consumer sentimentPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
VIX Spike: Is ALX Oncology Holdings Inc in accumulation or distribution phase2025 Technical Patterns & Verified Swing Trading Watchlist - baoquankhu1.vn
Investment Report: Will ALX Oncology Holdings Inc stock hit new highs in YEARIPO Watch & AI Forecasted Entry/Exit Points - baoquankhu1.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ALX Oncology increases shares reserved for inducement equity plan By Investing.com - Investing.com Nigeria
ALX Oncology increases shares reserved for inducement equity plan - Investing.com
ALX Oncology Expands Inducement Equity Plan for Hiring - TipRanks
Aug Volume: How does QuantumScape Corporation correlate with NasdaqEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
Downgrade Watch: Is Teledyne Technologies Incorporated a cyclical or defensive stockMarket Rally & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Highs Report: Does ALX Oncology Holdings Inc. have high return on assetsJuly 2025 Market Mood & AI Powered Buy and Sell Recommendations - bollywoodhelpline.com
Fed Watch: Will Hennessy Advisors Inc stock hit new highs in YEARLong Setup & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference - MarketBeat
ALX Oncology : Investor Presentation ALX presentation at JPM 2026 12Jan2026 FINAL (698186) - marketscreener.com
Aug Spikes: Will ALX Oncology Holdings Inc stock recover after earnings - baoquankhu1.vn
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks - Yahoo Finance
Stock Report: Why ALX Oncology Holdings Inc stock remains undervaluedPortfolio Performance Summary & AI Enhanced Trading Alerts - Bộ Nội Vụ
Is ALX Oncology Holdings Inc. stock trading near support levelsJuly 2025 Fed Impact & Weekly Top Performers Watchlists - Улправда
Hedge Fund Moves: How geopolitical tensions affect ALX Oncology Holdings Inc. stockJuly 2025 Update & Consistent Profit Trading Strategies - Улправда
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Why ALX Oncology Holdings Inc. stock remains undervaluedWeekly Market Report & Daily Momentum Trading Reports - Улправда
How ALX Oncology Holdings Inc. stock compares to market leadersJuly 2025 Momentum & Safe Capital Growth Stock Tips - Улправда
How geopolitical tensions affect ALX Oncology Holdings Inc. stock2025 Macro Impact & Verified Trade Idea Suggestions - Улправда
ALX Oncology Advances Separate Clinical Trials Evaluating - GlobeNewswire
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Meme Stocks: Will ALX Oncology Holdings Inc stock deliver consistent dividends2025 Valuation Update & Weekly Market Pulse Updates - moha.gov.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0% - Defense World
ALXOAmended Statement of Beneficial Ownership (3/a) - ADVFN
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights - ADVFN
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update - ADVFN
ALX Oncology (NASDAQ:ALXO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Aug PostEarnings: What technical charts say about ALX Oncology Holdings Inc. stock2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - DonanımHaber
What momentum indicators show for ALX Oncology Holdings Inc. stockMarket Risk Summary & AI Driven Price Forecasts - Улправда
Alx Oncology: A Study in Contrasting Market Sentiment - AD HOC NEWS
AIx 온콜로지 (ALXO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
AIx 온콜로지 주식 (ALXO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
1.53%
1.88%
자본화:
|
볼륨(24시간):